Previous close | 38.65 |
Open | 38.74 |
Bid | 35.75 x 800 |
Ask | 38.96 x 1000 |
Day's range | 38.09 - 39.08 |
52-week range | 26.25 - 43.57 |
Volume | |
Avg. volume | 382,711 |
Market cap | 2.476B |
Beta (5Y monthly) | 1.41 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of -1.61% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Fortress Biotech (FBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sutro Biopharma, Inc. (STRO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Xenon Pharmaceuticals (XENE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Xenon Pharmaceuticals ( NASDAQ:XENE ) Full Year 2022 Results Key Financial Results Net loss: US$124.9m (loss widened by...
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of 1.72% and 100%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
We think all investors should try to buy and hold high quality multi-year winners. While not every stock performs well...
Market forces rained on the parade of Xenon Pharmaceuticals Inc. ( NASDAQ:XENE ) shareholders today, when the analysts...
Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of -9.62% and 97.94%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
How far off is Xenon Pharmaceuticals Inc. ( NASDAQ:XENE ) from its intrinsic value? Using the most recent financial...
One thing we could say about the analysts on Xenon Pharmaceuticals Inc. ( NASDAQ:XENE ) - they aren't optimistic...
Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of -12.25% and 91.63%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Every investor in Xenon Pharmaceuticals Inc. ( NASDAQ:XENE ) should be aware of the most powerful shareholder groups...
We think all investors should try to buy and hold high quality multi-year winners. And we've seen some truly amazing...